Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.71 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.71 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.71 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.71 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.71 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.71 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468627 | 1.00 | LRRK2 (0.71) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL250564 | 0.89 | LRRK2 (0.56) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL250565 | 0.89 | LRRK2 (0.56) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477806 | 0.88 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477805 | 0.88 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7136579 | 0.86 | MAPT (0.63) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395409 | 0.84 | LRRK2 (0.76) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14674288 | 0.84 | LRRK2 (0.76) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18499298 | 0.84 | LRRK2 (0.72) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14674289 | 0.84 | LRRK2 (0.76) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| WO-1993012786-A1 | INDOLINONE DERIVATIVES | HOWARD HARRY R JR (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5064852-A | Antidiabetic agents; aldose reductase inhibitors | PFIZER INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4960785-A | Indolinone derivatives | PFIZER INC. (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0252713-B1 | INDOLINONE DERIVATIVES | PFIZER INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| EP-0252713-A1 | Indolinone derivatives | PFIZER INC. (US) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | LRRK2 1753/4885PSEN1 1618/4885PSEN2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.